Polypeptide composition for nursing skin and application thereof

The composition of β-alanylhydroxyprolyldiaminobutyrate and oligopeptide-215 inhibits the activity of tyrosinase and elastase and increases the content of silk polyprotein, which solves the difficulty in achieving simultaneously in the prior art. The skin problems of whitening, firming, moisturizing and repair have achieved a significant improvement in the effectiveness of multiple skin care.

CN119033618APending Publication Date: 2024-11-29SHENZHEN WINKEY TECHNOLOGY CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411516597.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

It is difficult to develop a polypeptide composition in the prior art that can simultaneously have the skin effects of whitening, firming, moisturizing, soothing and repairing, and effectively improve skin problems caused by photoaging.

Method used

Using a composition of beta-alanylhydroxyprolyldiaminobutyrate and oligopeptide-215, the content of silk polyprotein is increased by inhibiting the activities of tyrosinase, elastase and hyaluronidase, and the content of silk polyprotein is achieved. Works synergistically to achieve multiple skin care effects.

Benefits of technology

Significantly inhibit tyrosinase and elastase activity, reduce melanin synthesis and elastin hydrolysis, improve skin elasticity and firmness, enhance moisturizing ability, repair skin barriers, and achieve whitening, anti-aging, wrinkle removal, moisturizing and repairing effects .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033618A_ABST
    Figure CN119033618A_ABST
Patent Text Reader

Abstract

The invention discloses a polypeptide composition for nursing skin and application thereof, and relates to the technical field of polypeptides, and the polypeptide composition comprises beta-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215. The invention particularly relates to the polypeptide composition and application of the polypeptide composition in preparation of cosmetics.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the technical field of polypeptides, and in particular to a polypeptide composition for skin care and application thereof. Background Art

[0002] With the improvement of living standards, people are paying more and more attention to the problem of skin aging. Skin aging includes natural aging and photoaging. Among them, photoaging is the aging manifestation of skin after being damaged by ultraviolet light. When the skin is exposed to excessive ultraviolet radiation, the content of active oxygen in skin cells increases, causing the skin to have oxidative stress response and produce a large number of inflammatory factors. At this time, the skin will have an inflammatory reaction; in addition, ultraviolet rays can also activate the activity of matrix metalloproteinases, thereby accelerating the degradation of elastin and collagen, making the skin loose and losing elasticity. Skin exposed to ultraviolet rays for a long time will also stimulate melanocytes to produce a large amount of melanin, resulting in a large amount of pigment deposition in the skin, making the skin yellow and dark. Strong ultraviolet radiation can also cause damage to the skin barrier and increase transepidermal water loss. In general, the manifestations of skin aging are mainly skin sagging, decreased elasticity, wrinkles, excessive pigmentation, barrier damage, dry skin, etc.

[0003] Skin aging manifests itself in many ways. Active peptides are popular active ingredients in cosmetics in recent years. There are many types of active peptides, and different peptides can be used to solve different skin problems. For example, nonapeptide-1 has been widely used for whitening; palmitoyl tripeptide-5, palmitoyl pentapeptide-4 and other peptides are widely used for skin tightening. However, there may be antagonistic relationships between different peptides, and the use of multiple different peptides at the same time does not necessarily result in a peptide composition with multiple functions at the same time. Therefore, developing a product that has the functions of whitening, tightening, repairing, etc. at the same time, so as to more comprehensively improve the symptoms of skin aging, is still one of the problems that need to be solved. Summary of the invention

[0004] The present disclosure relates to a polypeptide composition and application thereof, wherein the polypeptide composition has the functions of caring for or treating skin or mucous membranes.

[0005] In one aspect, the present disclosure provides a polypeptide composition comprising β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215.

[0006] β-Alanyl Hydroxyprolyldiaminobutyroyl Benzylamide (INCI name: Beta-AlanylHydroxyprolyldiaminobutyroyl Benzylamide, National Cosmetics Registration No. 20210003) is a polypeptide derivative that can increase skin elasticity. It is a product independently developed by Shenzhen Vicky Technology Co., Ltd.

[0007] Oligopeptide-215 (INCI name: Oligopeptide-215, national cosmetics license number 20220012) is a peptide with skin repair effects and is a product independently developed by Shenzhen Vicky Technology Co., Ltd.

[0008] The inventors of the present disclosure surprisingly found that when β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215 were combined, it produced an unexpected effect of inhibiting tyrosinase activity, and could exert a whitening effect. In addition, the inventors of the present disclosure also found that after β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215 were combined, the two produced a synergistic effect, which could significantly improve the inhibitory effect on elastase activity, thereby providing a stronger skin tightening effect; it could significantly improve the inhibition rate of hyaluronidase activity, increase the content of filaggrin (FLG), and have a stronger moisturizing, soothing, and repairing effect. Therefore, after compounding β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215, a composite product with the effects of whitening, firming, moisturizing, soothing, and repairing can be obtained, which can effectively help the skin recover after exposure to the sun.

[0009] In some embodiments, the concentration ratio of β-alanylhydroxyprolyldiaminobutyric acid benzylamine and oligopeptide-215 is 3:(1~9).

[0010] In some embodiments, the concentration ratio of β-alanylhydroxyprolyldiaminobutyric acid benzylamine and oligopeptide-215 is 3:(1.5~6).

[0011] In some embodiments, the concentration ratio of β-alanylhydroxyprolyldiaminobutyric acid benzylamine and oligopeptide-215 is 3:1.5, 3:3, or 3:6.

[0012] Another aspect of the present disclosure provides a cosmetic comprising an effective amount of the above polypeptide composition and at least one additional ingredient.

[0013] "Effective amount" means an amount of the polypeptide composition of the present disclosure that is non-toxic but sufficient to provide the desired effect. The polypeptide composition of the present disclosure is used in the cosmetics of the present disclosure at an effective concentration to obtain the desired effect. In some embodiments, the concentration of the polypeptide composition is between 0.00000001% (by weight) and 20% (by weight) relative to the total weight of the cosmetic; in some embodiments, the concentration of the polypeptide composition is between 0.000001% (by weight) and 15% (by weight) relative to the total weight of the cosmetic; in some embodiments, the concentration of the polypeptide composition is between 0.0001% (by weight) and 10% (by weight) relative to the total weight of the cosmetic; in some embodiments, the concentration of the polypeptide composition is between 0.0001% (by weight) and 5% (by weight) relative to the total weight of the cosmetic.

[0014] In some embodiments, the dosage form of the cosmetic comprises ointment, cream, emulsion, aqueous solution, oil, gel, powder, tablet, mud, patch, film, aerosol, spray, freeze-dried preparation or nano preparation.

[0015] Another aspect of the present disclosure provides a use of the above-mentioned polypeptide composition in preparing a composition for inhibiting the activity of elastase, or in preparing a composition for increasing skin elasticity, or in preparing a composition for improving skin firmness, or in preparing a composition for anti-aging.

[0016] Another aspect of the present disclosure provides a use of the above-mentioned polypeptide composition in preparing a composition for inhibiting tyrosinase activity, inhibiting melanin production, whitening, removing spots, brightening skin color or eliminating uneven skin color.

[0017] Another aspect of the present disclosure provides a use of the above-mentioned polypeptide composition in preparing a composition for inhibiting hyaluronidase activity, increasing filaggrin content, moisturizing, soothing or repairing.

[0018] Another aspect of the present disclosure provides a use of the above polypeptide composition in preparing cosmetics.

[0019] In the present disclosure, the term "skin" is understood to refer to the multiple layers that make it up, from the uppermost layer or stratum corneum to the lowermost layer or subcutaneous tissue, both ends are included. These layers are composed of different types of cells, such as keratinocytes, fibroblasts, melanocytes, and / or adipocytes, etc. In the present disclosure, the term "skin" includes the scalp.

[0020] The term "skin care" refers to the maintenance and care of the skin, improving the condition of the skin, making it delicate, smooth, tender and healthy.

[0021] The present disclosure has the following advantages and effects:

[0022] 1. The polypeptide composition disclosed herein can effectively inhibit the activity of tyrosinase. Inhibiting the activity of tyrosinase can reduce the synthesis of melanin in an organism, thereby achieving the effects of whitening and lightening spots. Therefore, the polypeptide composition disclosed herein can reduce the synthesis of melanin and has the effects of whitening and removing spots.

[0023] 2. The polypeptide composition disclosed in the present invention can effectively inhibit the activity of elastase. Inhibiting the activity of elastase can inhibit the hydrolysis of elastin and increase the content of elastin in skin tissue. The lack of elastin is the main cause of skin aging, relaxation, sagging and fine wrinkles. Therefore, the polypeptide composition disclosed in the present invention is beneficial to increase skin elasticity, improve skin firmness, remove skin wrinkles, and has an anti-aging effect by inhibiting the activity of elastase.

[0024] 3. The polypeptide composition disclosed in the present invention can effectively inhibit the activity of hyaluronidase. Inhibiting the activity of hyaluronidase can reduce the decomposition of hyaluronic acid in cells, increase the content level of hyaluronic acid in cells, help increase the hydration of skin or mucous membranes, repair the skin barrier, and have the effects of moisturizing, soothing and repairing. Therefore, the polypeptide composition disclosed in the present invention can increase the content level of hyaluronic acid in cells by inhibiting the activity of hyaluronidase, and has the effects of moisturizing, soothing and repairing.

[0025] 4. The polypeptide composition disclosed in the present invention can effectively promote the expression of FLG. FLG is an important molecule that connects keratin fibers in the stratum corneum of human skin. With the help of FLG monomers, keratin fibers are regularly aggregated to form a solid physical barrier in the outermost layer of the epidermis, which can prevent the loss of epidermal moisture and the invasion of external allergic substances. Promoting the expression of FLG is conducive to repairing the skin barrier. Therefore, the polypeptide composition disclosed in the present invention has the effects of repairing and moisturizing.

[0026] The polypeptide composition disclosed in the present invention has the effects of inhibiting tyrosinase activity, elastase activity and hyaluronidase activity and promoting FLG expression, and can be used to restore skin condition after sun exposure and alleviate problems such as pigmentation, photoaging and skin damage after sun exposure. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the technical solution of the present disclosure, the drawings required for use in the description of the present disclosure will be briefly introduced below. Obviously, the drawings in the following description are only some embodiments of the present disclosure. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0028] Figure 1It is a result diagram of the tyrosinase activity measurement experiment in Example 1 of the present disclosure. DETAILED DESCRIPTION

[0029] In order to make the objects, features and advantages of the present disclosure more obvious and understandable, the present disclosure is further described in detail below in conjunction with the accompanying drawings and embodiments. Obviously, the described embodiments are part of the embodiments of the present disclosure, rather than all of the embodiments. Based on the embodiments in the present disclosure, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the claims attached to the present disclosure.

[0030] Unless otherwise specified, the experimental reagents and materials used in the present disclosure can be obtained commercially.

[0031] The compounding ratio of each polypeptide in the composition of the present disclosure embodiment is as follows: Composition β-Alanyl Hydroxyprolyl Diaminobutyric Acid Benzylamine (hereinafter referred to as Monopeptide A) Oligopeptide-215 (hereinafter referred to as single peptide B) Composition 1 3 9 Composition 2 3 6 Composition 3 3 3 Composition 4 3 1.5 Composition 5 3 1.2 Composition 6 3 1

[0032] Note: When the concentration of the composition is 500 ppm, if single peptide A: single peptide B = 3:3, it means that single peptide A is 250 ppm and single peptide B is 250 ppm.

[0033] Example 1 Tyrosinase activity assay

[0034] 1.1 Reagents and Materials

[0035] Mushroom tyrosinase, L-DOPA.

[0036] 1.2 Instruments

[0037] ELISA reader, clean bench.

[0038] 1.3 Samples to be tested and grouping

[0039] 1.3.1 Samples to be tested

[0040] Composition 1, composition 2, composition 3, composition 4, composition 5, and composition 6: the test concentration of all the above compositions is 500 ppm.

[0041] 1.3.2 Grouping

[0042] Sample group: test sample, tyrosinase, PBS, L-DOPA;

[0043] Sample zeroing group: test sample, PBS, L-DOPA;

[0044] Blank control group: PBS, tyrosinase, L-DOPA;

[0045] Blank zero adjustment group: PBS, L-DOPA.

[0046] 1.4 Experimental methods

[0047] Take a 96-well plate, add 50μL of the sample to be tested and 50μL of tyrosinase (25U / mL) to the sample group; add 50μL of the sample to be tested and 50μL of PBS to the sample zeroing group; add 50μL of PBS and 50μL of tyrosinase (25U / mL) to the blank control group; add 100μL of PBS to the blank zeroing group. After incubating at 37℃ for 5min, add 50μL of PBS and 50μL of L-DOPA (0.5mmol / L) to each well and incubate at 37℃ for 10min. Measure OD at 492nm 492 value.

[0048] Tyrosinase inhibition rate (%) =

[0049] Where: A1 is the OD of the sample zeroing group 492 value, A2 is the OD of the sample group 492 A3 is the OD of the blank zero adjustment group. 492 A4 is the OD of the blank control group. 492 value.

[0050] 1.5 Experimental Results

[0051] L-DOPA is a substrate of tyrosinase. Under the catalytic action of tyrosinase, L-DOPA is oxidized into black dopaquinone substances and absorbs visible light at a wavelength of 492nm. In this experiment, the test sample is used to treat tyrosinase, and the reaction amount of L-DOPA is detected to determine whether the test sample disclosed in the present invention can inhibit the activity of tyrosinase.

[0052] The results of the test samples' effects on tyrosinase activity inhibition are shown in Figure 1 . The results show that the inhibition rate of composition 1 to tyrosinase activity is 15.29%, the inhibition rate of composition 2 to tyrosinase activity is 8.98%, the inhibition rate of composition 3 to tyrosinase activity is 12.32%, the inhibition rate of composition 4 to tyrosinase activity is 13.44%, the inhibition rate of composition 5 to tyrosinase activity is 16.41%, and the inhibition rate of composition 6 to tyrosinase activity is 13.59%. The experimental results show that the compositions 1-6 disclosed in the present invention all have a significant inhibitory effect on tyrosinase activity. It can be seen that combining β-alanylhydroxyprolyldiaminobutyric acid benzylamine and oligopeptide-215 can produce new effects. The combination has an excellent effect of inhibiting tyrosinase activity, can inhibit melanin production, can be used to improve skin problems such as melanin deposition and chloasma, and achieve whitening, freckle removal, brightening skin color or eliminating uneven skin color.

[0053] Example 2 Elastase activity assay experiment

[0054] 2.1 Reagents and Materials

[0055] PBS buffer, elastase solution, AAAPAN solution. The elastase solution and AAAPAN solution are both prepared with PBS buffer.

[0056] 2.2 Instruments

[0057] ELISA reader, electronic balance.

[0058] 2.3 Samples to be tested and grouping

[0059] 2.3.1 Samples to be tested

[0060] β-Alanylhydroxyprolyldiaminobutyric acid benzylamine (single peptide A), oligopeptide-215 (single peptide B), composition 2, and composition 4, the test concentration is 100 ppm.

[0061] 2.3.2 Grouping

[0062] Sample group: test sample, PBS, elastase, AAAPAN;

[0063] Sample zeroing group: test sample, PBS, AAAPAN;

[0064] Blank control group: PBS, elastase, AAAPAN;

[0065] Blank zero adjustment group: PBS, AAAPAN.

[0066] 2.4 Experimental Methods

[0067] Take a 96-well plate, add 85μL PBS, 15μL test sample, and 25μL elastase solution (2mg / mL) to the sample group; add 110μL PBS and 15μL test sample to the sample zeroing group; add 100μL PBS and 25μL elastase solution (2mg / mL) to the blank control group; add 125μL PBS to the blank zeroing group. After incubating at 25℃ for 15min, add 25μL AAAPAN solution (1.015mmol / L) to each well and incubate at 25℃ for 15min. Measure OD at 410nm 410 value.

[0068] Elastase inhibition rate (%) =

[0069] Where: A1 is the OD of the sample zeroing group 410 value, A2 is the OD of the sample group 410 A3 is the OD of the blank zero adjustment group. 410A4 is the OD of the blank control group. 410 value.

[0070] 2.5 Experimental results

[0071] AAAPAN (N-succinyl-alanine-alanine-alanine-p-nitroaniline) is a substrate of elastase. Under the catalytic action of elastase, AAAPAN will be decomposed, and the decomposition product will absorb visible light of 410nm wavelength. In this experiment, the test sample is used to treat elastase, and the reaction amount of AAAPAN is detected to determine whether the sample disclosed in the present invention can inhibit the activity of elastase.

[0072] The results of the effects of the test samples on the inhibition of elastase activity are shown in Table 1.

[0073] Table 1 Effects of test samples on inhibition of elastase activity Test samples Elastase inhibition rate (%) (Mean±SD) Monopeptide A 47.02±4.45 Peptide B 30.47±1.10 Composition 2 63.57±7.19* ## Composition 4 64.89±7.56* ##

[0074] Note: * indicates p<0.05 compared with single peptide A; ## indicates p<0.01 compared with single peptide B.

[0075] The results show that at the same concentration, the inhibition rates of composition 2 and composition 4 on elastase activity are significantly higher than the inhibition rates of elastase when β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215 are used alone, which fully proves that the combination of β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215 can produce a synergistic effect. It can be seen that the composition disclosed in the present invention has an excellent effect of inhibiting elastase activity, can be used to improve skin problems such as skin sagging and skin wrinkles, effectively increase skin elasticity and / or improve skin firmness, and achieve anti-aging, firming, and wrinkle removal effects.

[0076] Example 3 Hyaluronidase activity assay

[0077] 3.1 Reagents and Materials

[0078] Sodium acetate buffer (pH=5.6), hyaluronidase, calcium chloride, sodium hyaluronate, acetylacetone, anhydrous ethanol, sodium carbonate, P-DAB (obtained by uniformly mixing p-dimethylaminobenzaldehyde (0.8 g) and concentrated hydrochloric acid (15 mL) and an equal amount of glacial acetic acid).

[0079] 3.2 Instruments

[0080] ELISA reader, electronic balance.

[0081] 3.3 Samples to be tested and grouping.

[0082] 4.3.1 Samples to be tested

[0083] The test concentrations of single peptide A, single peptide B, and composition 2 were all 200 ppm.

[0084] 4.3.2 Grouping

[0085] Sample group: test sample, hyaluronidase, sodium hyaluronate;

[0086] Sample zeroing group: test sample, sodium acetate buffer;

[0087] Blank control group: distilled water, hyaluronidase, sodium hyaluronate;

[0088] Blank zero adjustment group: distilled water, sodium acetate buffer.

[0089] 3.4 Experimental methods

[0090] Hyaluronidase and sodium hyaluronate were dissolved in sodium acetate buffer.

[0091] Take a 96-well plate, add 25μL of the sample to be tested and 25μL of hyaluronidase (1000U / mL) to the sample group; add 25μL of the sample to be tested and 25μL of sodium acetate buffer to the sample zeroing group; add 25μL of distilled water and 25μL of hyaluronidase (1000U / mL) to the blank control group; add 25μL of distilled water and 25μL of sodium acetate buffer to the blank zeroing group. After shaking in a 37℃ constant temperature air bath for 20min, add 5μL of calcium chloride solution (2.5mol / L) to each well, and shake in a 37℃ constant temperature air bath for 20min. Add 25μL of sodium hyaluronate (1mg / mL) to the sample group and the blank control group, and add 25μL of sodium acetate buffer to the sample zeroing group and the blank zeroing group, shake in a 37℃ constant temperature air bath for 40min, and then leave at room temperature for 10min. Add 25 μL of distilled water, 5 μL of sodium hydroxide solution (5 mol / L), and 25 μL of acetylacetone solution to each well and place in a 90°C oven for 15 min, then place in an ice bath for 10 min, and finally place at room temperature for 10 min. Add 50 μL of P-DAB to each well, then add 100 μL of anhydrous ethanol, place at room temperature for 30 min, and measure OD at 570 nm. 570 value.

[0092] Hyaluronidase inhibition rate (%) =

[0093] Where: A1 is the OD of the sample zeroing group 570 value, A2 is the sample group OD 570 A3 is the OD of the blank zero adjustment group. 570 A4 is the OD of the blank control group. 570 value.

[0094] 3.5 Experimental Results

[0095] Hyaluronidase activity is closely related to type I allergic reactions. Inhibiting hyaluronidase activity can play a soothing and anti-allergic role. Therefore, inhibiting hyaluronidase activity is often used as an evaluation indicator for studying soothing and anti-allergic effects. In addition, hyaluronidase is a hydrolase that degrades hyaluronic acid. Inhibiting hyaluronidase activity can reduce the degradation of hyaluronic acid in cells and increase the content of hyaluronic acid in cells, which is beneficial to increase the hydration of the skin or mucous membranes, repair the skin barrier, and play a moisturizing, soothing, and repairing role.

[0096] Sodium hyaluronate is a substrate of hyaluronidase. Under the catalytic action of hyaluronidase, sodium hyaluronate is degraded to generate glucuronic acid and N-acetylglucosamine, which develop color and absorb visible light of 570nm wavelength under the action of P-DAB. In this experiment, the test sample is used to treat hyaluronidase, and the reaction amount of sodium hyaluronate is detected to determine whether the test sample disclosed in the present invention can inhibit the activity of hyaluronidase.

[0097] The results of the effects of the test samples on the inhibition of hyaluronidase activity are shown in Table 2.

[0098] Table 2 Effects of test samples on inhibition of hyaluronidase activity Test samples Hyaluronidase inhibition rate (%) (Mean±SD) Monopeptide A 45.59±8.88 Peptide B 18.42±5.64 Composition 2 77.59±7.45* ##

[0099] Note: * indicates p<0.05 compared with single peptide A; ## indicates p<0.01 compared with single peptide B.

[0100] The results show that at the same concentration, the inhibition rate of composition 2 on hyaluronidase activity is significantly higher than that of the hyaluronidase inhibition rate of β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215 alone, which fully proves that the combination of β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215 can produce a synergistic effect. It can be seen that the composition disclosed in the present invention has a more excellent effect of inhibiting hyaluronidase activity, can be used to repair the skin barrier, and has the effects of moisturizing, soothing and repairing.

[0101] Example 4 FLG content test

[0102] 4.1 Reagents and Materials

[0103] Trypsin, complete culture medium, PBS, RIPA lysis buffer, FLG ELISA kit.

[0104] 4.2 Instruments

[0105] Carbon dioxide incubator, clean bench, vortexer, and microplate reader.

[0106] 4.3 Cell lines

[0107] HaCaT cells.

[0108] 4.4 Samples to be tested and grouping

[0109] Sample group: single peptide A, single peptide B, combination 2, all with a concentration of 25 ppm;

[0110] Blank control group (Control): PBS;

[0111] UV group: PBS+UV irradiation.

[0112] 4.5 Experimental methods

[0113] Take a bottle of cells in good condition in the exponential growth phase, add 0.25% trypsin digestion solution, digest to make the adherent cells fall off, and count (1-4)×10 5 / mL, and make a cell suspension. Inoculate in a 12-well plate, add complete medium, and culture in a CO2 incubator for 24 h. After the culture, aspirate the complete medium in the well, add PBS, and expose the sample group and UV group to UVB light for 15 min, while the blank control group is not irradiated. After the irradiation, aspirate PBS, add complete medium to the sample group, UV group, and blank control group, add the sample to be tested (the final concentration of the test is 25ppm), and add PBS equal to the volume of the sample to be tested to the UV group and blank control group, and culture for 48h. After the culture, collect the cells, centrifuge and discard the supernatant, add RIPA lysis buffer, shake with a vortexer 3 times (30 s / time, 3 min interval), and centrifuge at 12000 rpm*10 min. Aspirate the supernatant and test it with an ELISA kit to calculate the FLG content.

[0114] 4.6 Experimental Results

[0115] Filaggrin (FLG) is an important component of the skin barrier. It plays an important role in maintaining the physical strength of the stratum corneum and reducing transepidermal water loss, which is beneficial to maintaining barrier integrity and moisturizing. Therefore, the expression of FLG can be used as an indicator to evaluate the effect of skin barrier repair. By testing the effect of a substance on FLG expression, the effect of the substance on skin barrier repair can be evaluated. Increased expression of FLG is beneficial to repair the skin barrier, improve skin barrier function, and enhance the skin's moisturizing ability.

[0116] The results of the test samples’ effects on FLG content are shown in Table 3.

[0117] Table 3 Effect of test samples on FLG content Test samples FLG content (ng / mg) (Mean±SD) Control 32.79±2.50 UV 4.49±0.51 Monopeptide A 6.68±0.82 Peptide B 8.15±0.23 Composition 2 9.37±0.37* #

[0118] Note: * indicates p<0.05 compared with single peptide A; # indicates p<0.05 compared with single peptide B.

[0119] The results show that compared with the UV group, single β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215 can promote FLG expression to a certain extent; compared with single β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and single oligopeptide-215, at the same concentration, the composition 2 of the present disclosure can more significantly increase the FLG content, proving that the combination of β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215 produces a synergistic effect. Therefore, the composition of the present disclosure can significantly promote keratinocytes to express FLG, increase FLG content, thereby repairing or enhancing the skin barrier, and has the effects of repairing and moisturizing.

[0120] In the present disclosure, relational terms such as first and second, etc. are used only to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or terminal device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or terminal device. In the absence of further restrictions, the elements defined by the statement "comprise one..." do not exclude the presence of other identical elements in the process, method, article or terminal device including the elements.

[0121] Although the specific embodiments of the present disclosure have been described for illustrative purposes, various modifications or improvements may be made by those skilled in the art without departing from the spirit and scope of the present disclosure. These modifications or improvements should all fall within the scope of the appended claims of the present disclosure.

Claims

1. A polypeptide composition, characterized in that: Including β-alanylhydroxyprolyldiaminobutyric acid benzylamine and oligopeptide-215.

2. The polypeptide composition according to claim 1, characterized in that: The concentration ratio of the β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215 is 3:(1-9).

3. The polypeptide composition according to claim 2, characterized in that: The concentration ratio of the β-alanyl hydroxyprolyl diaminobutyric acid benzylamine and oligopeptide-215 is 3:(1.5~6).

4. The polypeptide composition according to claim 2, characterized in that: The concentration ratio of β-alanylhydroxyprolyldiaminobutyric acid benzylamine and oligopeptide-215 is 3:

6.

5. A cosmetic, characterized in that: The invention comprises an effective amount of the polypeptide composition according to any one of claims 1 to 4, and at least one additional ingredient.

6. The cosmetic according to claim 5, characterized in that: The dosage forms of the cosmetics include ointments, creams, emulsions, aqueous solutions, oils, gels, powders, tablets, muds, patches, films, aerosols, sprays, freeze-dried preparations or nano preparations.

7. Use of the polypeptide composition according to any one of claims 1 to 4 in the preparation of a composition for inhibiting elastase activity, increasing skin elasticity, improving skin firmness or anti-aging.

8. Use of the polypeptide composition according to any one of claims 1 to 4 in the preparation of a composition for inhibiting tyrosinase activity, inhibiting melanin production, whitening, removing spots, brightening skin color or eliminating uneven skin color.

9. Use of the polypeptide composition according to any one of claims 1 to 4 in the preparation of a composition for inhibiting hyaluronidase activity, increasing filaggrin content, moisturizing, soothing or repairing.

10. Use of the polypeptide composition according to any one of claims 1 to 4 in the preparation of cosmetics.

Citation Information

Patent Citations

  • Total-effect eye cream and preparation method thereof

    CN115282078A

  • Beauty composition as well as preparation method and application thereof

    CN117771121A